CC
TXMD icon

Clearline Capital’s TherapeuticsMD TXMD Stock Holding History

Clearline Capital’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.28M Hold
635,222
– – 0.07% 93
2025
Q4 		$1.04M Hold
635,222
– – 0.05% 91
2025
Q3 		$683K Hold
635,222
– – 0.03% 99
2025
Q2 		$737K Hold
635,222
– – 0.03% 98
2025
Q1 		$588K Hold
635,222
– – 0.04% 103
2024
Q4 		$546K Sell
635,222
-1,400
-0.2% -$1.97K 0.07% 89
2024
Q3 		$1.06M Hold
636,622
– – 0.04% 113
2024
Q2 		$1.02M Buy
636,622
+101,282
+19% +$204K 0.03% 116
2024
Q1 		$1.23M Buy
535,340
+69,129
+15% +$160K 0.06% 98
2023
Q4 		$1.05M Buy
466,211
+10,823
+2% +$26.1K 0.06% 83
2023
Q3 		$1.38M Buy
455,388
+16
+0% +$61 0.12% 97
2023
Q2 		$1.88M Buy
455,372
+35,947
+9% +$141K 0.11% 77
2023
Q1 		$1.57M Buy
419,425
+185,385
+79% +$889K 0.24% 66
2022
Q4 		$1.31M Buy
+234,040
New +$1.38M 0.23% 79
2020
Q4 		– Sell
-14,579
Closed -$1.15M – 96
2020
Q3 		$1.15M Buy
+14,579
New +$1.16M 0.3% 60
2020
Q1 		– Sell
-616
Closed -$75K – 86
2019
Q4 		$75K Buy
+616
New +$88.6K 0.03% 54
2017
Q1 		– Sell
-935
Closed -$270K – 67
2016
Q4 		$270K Buy
+935
New +$290K 0.12% 45

Other funds holding TXMD

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Clearline Capital's TXMD Position: Q1 2026 in Review

Clearline Capital held its TherapeuticsMD (TXMD) position steady in Q1 2026 at 635,222 shares worth $1.28M. The position accounts for 0.07% of the portfolio, ranked #93.

Clearline Capital first reported a position in TXMD in Q4 2016 and has held it in 17 quarters since. The position peaked at $1.88M in Q2 2023. 49 funds tracked by Wall St. Rank hold TXMD as of Q1 2026.

  • Clearline Capital held 635,222 shares of TherapeuticsMD worth $1.28M as of Q1 2026.
  • Clearline Capital left its TherapeuticsMD share count unchanged in Q1 2026.
  • TherapeuticsMD made up 0.07% of Clearline Capital's portfolio in Q1 2026, its #93 holding.
  • Clearline Capital first reported a position in TherapeuticsMD in Q4 2016 and has held it in 17 quarters since.
  • Clearline Capital's TherapeuticsMD position peaked at $1.88M in Q2 2023.
  • 49 funds tracked by Wall St. Rank held TherapeuticsMD as of Q1 2026.

Based on Clearline Capital's 13F filing for Q1 2026, filed 15 May 2026.